ALX Oncology Holdings (ALXO) stock
ALXO's Quality Score rose 1 point on Tue, Oct 6, to -5. Had its narrowest day in a week.
Follow ALXO's trial news. Pro members can get an alert when ALX Oncology Holdings files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Holding it back
Below a falling 200-day average, down over one year, down over two years.
2 more reasons behind ALXO's -5, for Pro members
What's next for ALXO, and how long its cash lasts
From ALX Oncology Holdings’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 8 quarters
Dilution on the horizon
- Shelf registration (S-3, filed Mar 6, 2025)
- At-the-market share sales program (S-3, filed Mar 6, 2025)
Insiders
CEO Jason Lettmann sold 2,230 shares on Aug 17. 7 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 49% in 3 months, 34% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 15% over the same 3 months.
−3Long-term trend below a falling 200-day average, down over one year, down over two years
2 more things pulling ALXO's score down, for Pro members
What's next
Expected to report Fri Nov 6, before the open
After its last 4 reports it closed +7.0% on average, higher 3 of 4 times.
What would turn ALXO's score around: 6 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
ALXO has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1421.5
- MACD (12, 26, 9)Below signal
- 50-day average$1.82
- 200-day average$1.84
- ADX 1438.8
- Support$1.07
- Resistance$1.56
- Bollinger Bands (20, 2)Inside
- Volume0.8x
How ALXO ranks in Biotech
ALXO is #245 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA6/1419
ONC6/1418
EXEL6/1416
ALNYOpen for its score
ALTOpen for its score
AMGNOpen for its score
AMLXOpen for its score
ALXO1/14-5
When does ALXO report earnings, and what happens after?
Expected to report Fri Nov 6, before the open (in 31 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026Before open | Before open | +1.0% | +9.9% | +4.7% |
| May 8, 2026Before open | Before open | +1.1% | +11.2% | +9.1% |
| Feb 27, 2026Before open | Before open | -8.9% | -10.2% | -9.4% |
| Nov 7, 2025Before open | Before open | +2.5% | +16.9% | +3.4% |
Who is trading ALXO
ALXO insider trades
2 insiders sold $8K across 3 filings in the last 6 months. No open-market buys on record. The newest:
ALXO's officers and directors
Officers and directors with a Form 4 here in the last 3 months. Open one for their trades at every company.
About ALX Oncology Holdings
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of ALXO's score, with the points and the reason
- All 14 checks on ALXO and on all 3,244 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on ALXO
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.